Trial Profile
Phase I Trial Of Escalating Oral Doses Of SCH 66336 In Pediatric Patients With Refractory Or Recurrent Brain Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 30 Oct 2009
Price :
$35
*
At a glance
- Drugs Lonafarnib (Primary)
- Indications Brain cancer
- Focus Adverse reactions; Pharmacokinetics
- 20 Oct 2009 Actual patient number (53) added as reported by ClinicalTrials.gov.
- 21 Aug 2007 Status change from in progress to completed.
- 15 Oct 2005 New trial record.